Tag: ALKIVIA
-
Vyvgart Moves Into Autoimmune Muscle Disease After Phase 3 Win
Vyvgart Hytrulo met the primary endpoint in the Phase 3 ALKIVIA study, strengthening argenx’s case for expanding FcRn inhibition into autoimmune muscle disease.
Vyvgart Hytrulo met the primary endpoint in the Phase 3 ALKIVIA study, strengthening argenx’s case for expanding FcRn inhibition into autoimmune muscle disease.